Zobrazeno 1 - 5
of 5
pro vyhledávání: '"respuesta tumoral"'
Autor:
Lara Cárdenas, July Patricia
Publikováno v:
Chun S, Yu H, Chan SL, Lee KF, Wai J, Hui Y, et al. Ablative Chemoembolization for Hepatocellular Carcinoma : A Prospective Phase I Case-Control Comparison with Conventional. Radiology. 2018;000(0):1–9
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1
Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, et al. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clin Res Hepatol Gastroenterol. 2018;03(014):10
Hussain SM, Reinhold C, Mitchell DG. Cirrhosis and lesion characterization at MR imaging. Radiographics. 2009;29:1637–52
Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 Version of LI-RADS for CT and MR Imaging: An Update. RadioGraphics. 2017;37(7):1994– 2017
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101(February 2017):72–81
Edison J, Ort P, Carlos J, Guti R. Epidemiología y factores de riesgo. Asoc Colomb Gastroenterol Endosc Dig Coloproctología y Hepatol. 2013;7–11
Cortes-mancera F, Loureiro CL, Hoyos S, Restrepo J, Correa G, Jaramillo S, et al. Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat. 2011;2011:10
Lu SN, Wang JH, Su CW, Wang TE, Dai CY, Chen CH, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117(5):381–403
Parente DB, Perez RM, Araujo AE, Oliveira Neto JA, Marchiori E, Constantino CP, et al. MRI in hypervascular noduls in cyrrotic liver: A Diag-nostic Dilemma. RadioGraphics. 2012;32:767–87.
LI RADS [Internet]. Disponible en: https://www.acr.org/ClinicalResources/Reporting-and-Data-Systems/LI-RADS
Purysko AS, Remer EM, Coppa CP, Leão Filho HM, Thupili CR, Veniero JC. LI-RADS: A Case-based Review of the New Categorization of Liver Findings in Patients with EndStage Liver Disease. RadioGraphics. 2012;32(7):1977–95
Topalian SL, Drake CG, Pardoll DM. Perspective Immune Checkpoint Blockade : A Common Denominator Approach to Cancer Therapy. Cancer Cell [Internet]. 2015;27(4):450–61. Disponible en: http://dx.doi.org/10.1016/j.ccell.2015.03.001
Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Sherman M, Gores G. Hepatocellular carcinoma. Primer. 2016;2
Perez Hidalgo JM, Beltran OA. Tratamiento intervencionista. Asoc Colomb Gastroenterol Endosc Dig Coloproctología y Hepatol. 2013;28(3):21–7
Ahsun R, Khairuddin M, Frank H M, Paul N, Laura M K, Robert J L, et al. Role of EASL, RECIST and WHO Response Guidelines Alone or in Combination for Hepatocellular Carcinoma: Radiologic-Pathologic Correlation. J Hepatol. 2011;54(4):695 – 704
Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of Hepatocellular Carcinoma with Extrahepatic Collateral Blood Supply: Anatomic and Technical Considerations. RadioGraphics. 2017;37(3):963–77
Peng Z, Mei J, Qian G. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. 2019;(4)
De D, Sastre J, Martí-bonmati L, Llovet JM, Bilbao JI, Sangro B, et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH. 2016;(xx):1–22. Disponible en: https://servei.org/wpcontent/uploads/GPC_550_Carcinoma_Hepatocelular_2016.pdf
Cruz M, Hernández Martínez E, Correa A, Huitzil Meléndez LM, Vázquez FD. Embolización blanda vs . quimioembolización para tratamiento de carcinoma hepatocelular. Gac Mex Oncol. 2013;12(5):312–6
National Cancer Institute, Bethesda EU. Common Terminology Criteria for Adverse Events V3.0 (CTCAE). Cancer Ther Eval Progr 1-1. 2006
National Cancer Institute, Bethesda EU. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Cancer Institute. Cancer Ther Eval Progr. 2010
Yang H, Lee J, Lee DH, Kim H, Lee JM. Hepatocellular Carcinoma : Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology. 2014;271(3):909–18
Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, et al. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Cardiovasc Intervent Radiol. 2018;41(4):587–93
Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108(6):1252–9
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona2000 EASL conference. J Hepatol. 2001;35(3):421–30
Adulto DEL, Cantera CM, Familia M De, Passeig CAP, Joan DS, Català I, et al. Butlletí d ’ informació terapèutica. Butlletì d´informaciò Ter. 2017;28(9):67–74.
McEvoy SH, McCarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, et al. Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. RadioGraphics. 2013;33(6):1653–68
Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol. 2014;20(12):3069–77
Lencioni R, Llovet JM. Modified RECIST ( mRECIST ) Assessment for Hepatocellular Carcinoma. 2010;1(212):52–60
Dufour JF, Greten TF, Raymond E, Roskams T, De T, Ducreux M, et al. Clinical Practice Guidelines EASL – EORTC Clinical Practice Guidelines : Management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol [Internet]. 2012;56(4):908–43. Disponible en: http://dx.doi.org/10.1016/j.jhep.2011.12.001
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;Dec;5((6)):649–55
Sarasin F, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–34
Alejandro F, María E R, Carlos R, Jordi B. Current Strategy for Staging and Treatment-The BCLC Update and Future Prospects.pdf. Semin Liver Dis. 2010;30(1):61–74
Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2017;34(17):2046–53
Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol. 2017;67(1):173–83.
Llovet JM, Real MI, Montana X, Planas R. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1
Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, et al. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clin Res Hepatol Gastroenterol. 2018;03(014):10
Hussain SM, Reinhold C, Mitchell DG. Cirrhosis and lesion characterization at MR imaging. Radiographics. 2009;29:1637–52
Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 Version of LI-RADS for CT and MR Imaging: An Update. RadioGraphics. 2017;37(7):1994– 2017
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101(February 2017):72–81
Edison J, Ort P, Carlos J, Guti R. Epidemiología y factores de riesgo. Asoc Colomb Gastroenterol Endosc Dig Coloproctología y Hepatol. 2013;7–11
Cortes-mancera F, Loureiro CL, Hoyos S, Restrepo J, Correa G, Jaramillo S, et al. Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat. 2011;2011:10
Lu SN, Wang JH, Su CW, Wang TE, Dai CY, Chen CH, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117(5):381–403
Parente DB, Perez RM, Araujo AE, Oliveira Neto JA, Marchiori E, Constantino CP, et al. MRI in hypervascular noduls in cyrrotic liver: A Diag-nostic Dilemma. RadioGraphics. 2012;32:767–87.
LI RADS [Internet]. Disponible en: https://www.acr.org/ClinicalResources/Reporting-and-Data-Systems/LI-RADS
Purysko AS, Remer EM, Coppa CP, Leão Filho HM, Thupili CR, Veniero JC. LI-RADS: A Case-based Review of the New Categorization of Liver Findings in Patients with EndStage Liver Disease. RadioGraphics. 2012;32(7):1977–95
Topalian SL, Drake CG, Pardoll DM. Perspective Immune Checkpoint Blockade : A Common Denominator Approach to Cancer Therapy. Cancer Cell [Internet]. 2015;27(4):450–61. Disponible en: http://dx.doi.org/10.1016/j.ccell.2015.03.001
Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Sherman M, Gores G. Hepatocellular carcinoma. Primer. 2016;2
Perez Hidalgo JM, Beltran OA. Tratamiento intervencionista. Asoc Colomb Gastroenterol Endosc Dig Coloproctología y Hepatol. 2013;28(3):21–7
Ahsun R, Khairuddin M, Frank H M, Paul N, Laura M K, Robert J L, et al. Role of EASL, RECIST and WHO Response Guidelines Alone or in Combination for Hepatocellular Carcinoma: Radiologic-Pathologic Correlation. J Hepatol. 2011;54(4):695 – 704
Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of Hepatocellular Carcinoma with Extrahepatic Collateral Blood Supply: Anatomic and Technical Considerations. RadioGraphics. 2017;37(3):963–77
Peng Z, Mei J, Qian G. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. 2019;(4)
De D, Sastre J, Martí-bonmati L, Llovet JM, Bilbao JI, Sangro B, et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH. 2016;(xx):1–22. Disponible en: https://servei.org/wpcontent/uploads/GPC_550_Carcinoma_Hepatocelular_2016.pdf
Cruz M, Hernández Martínez E, Correa A, Huitzil Meléndez LM, Vázquez FD. Embolización blanda vs . quimioembolización para tratamiento de carcinoma hepatocelular. Gac Mex Oncol. 2013;12(5):312–6
National Cancer Institute, Bethesda EU. Common Terminology Criteria for Adverse Events V3.0 (CTCAE). Cancer Ther Eval Progr 1-1. 2006
National Cancer Institute, Bethesda EU. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Cancer Institute. Cancer Ther Eval Progr. 2010
Yang H, Lee J, Lee DH, Kim H, Lee JM. Hepatocellular Carcinoma : Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology. 2014;271(3):909–18
Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, et al. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Cardiovasc Intervent Radiol. 2018;41(4):587–93
Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108(6):1252–9
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona2000 EASL conference. J Hepatol. 2001;35(3):421–30
Adulto DEL, Cantera CM, Familia M De, Passeig CAP, Joan DS, Català I, et al. Butlletí d ’ informació terapèutica. Butlletì d´informaciò Ter. 2017;28(9):67–74.
McEvoy SH, McCarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, et al. Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. RadioGraphics. 2013;33(6):1653–68
Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol. 2014;20(12):3069–77
Lencioni R, Llovet JM. Modified RECIST ( mRECIST ) Assessment for Hepatocellular Carcinoma. 2010;1(212):52–60
Dufour JF, Greten TF, Raymond E, Roskams T, De T, Ducreux M, et al. Clinical Practice Guidelines EASL – EORTC Clinical Practice Guidelines : Management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol [Internet]. 2012;56(4):908–43. Disponible en: http://dx.doi.org/10.1016/j.jhep.2011.12.001
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;Dec;5((6)):649–55
Sarasin F, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–34
Alejandro F, María E R, Carlos R, Jordi B. Current Strategy for Staging and Treatment-The BCLC Update and Future Prospects.pdf. Semin Liver Dis. 2010;30(1):61–74
Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2017;34(17):2046–53
Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol. 2017;67(1):173–83.
Llovet JM, Real MI, Montana X, Planas R. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
El carcinoma hepatocelular (CHC) es la segunda causa de muerte relacionada con cáncer a nivel global, en Colombia se estima una incidencia de 2 casos por cada 100.000 habitantes; a nivel mundial los virus de la hepatitis B y C conforman los factores
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a7fd8fd99b60ebbf9a40e475efd200
https://repository.urosario.edu.co/handle/10336/32176
https://repository.urosario.edu.co/handle/10336/32176
Autor:
Eduardo Mordojovich Z., Christian Jensen B., Ernesto Melkonian T., Constanza Villalón M., Daniella Espínola M., Aldo Cuneo Z., Leonardo Espíndola S., Pablo Soffia S.
Publikováno v:
Revista de cirugía v.71 n.1 2019
SciELO Chile
CONICYT Chile
instacron:CONICYT
SciELO Chile
CONICYT Chile
instacron:CONICYT
Introduccion: El cancer colorrectal se ha convertido en el tercer cancer a nivel mundial en cuanto a incidencia y cuarto en mortalidad. Al diagnostico, aproximadamente el 25% de los pacientes tendran metastasis hepaticas. Con tratamiento adecuado el
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9957ab0dc0b93cf3bd3460150f1026
https://doi.org/10.4067/s0718-40262019000100055
https://doi.org/10.4067/s0718-40262019000100055
Autor:
Mordojovich Z., Eduardo, Jensen B., Christian, Melkonian T., Ernesto, Villalón M., Constanza, Espínola M., Daniella, Cuneo Z., Aldo, Espíndola S., Leonardo, Soffia S., Pablo
Publikováno v:
Revista de cirugía, Volume: 71, Issue: 1, Pages: 55-60, Published: 2019
Resumen Introducción: El cáncer colorrectal se ha convertido en el tercer cáncer a nivel mundial en cuanto a incidencia y cuarto en mortalidad. Al diagnóstico, aproximadamente el 25% de los pacientes tendrán metástasis hepáticas. Con tratamien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______614::7ee3d7683818c58ec3f3c7e748c5e9f0
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S2452-45492019000100055&lng=en&tlng=en
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S2452-45492019000100055&lng=en&tlng=en
Publikováno v:
Repositorio UN
Universidad Nacional de Colombia
instacron:Universidad Nacional de Colombia
Universidad Nacional de Colombia
instacron:Universidad Nacional de Colombia
Cuando se aplica un campo eléctrico alterno a un tejido biológico, su conductividad y permitividad dieléctrica están determinadas por la composición iónica de los medios extra e intracelular, la distribución y la estructura de las células que
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7f31af0d0e8a22043b02dde00d6a898d
http://bdigital.unal.edu.co/9113/
http://bdigital.unal.edu.co/9113/
Autor:
Jaka A; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España. Electronic address: ajaka@aedv.es., Gutiérrez-Rivera A; Laboratorio de Ingeniería tisular, Instituto Biodonostia, Hospital Universitario Donostia, San Sebastián, España., López-Pestaña A; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España., del Alcázar E; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España., Zubizarreta J; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España., Vildosola S; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España., Arregui MA; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España., Sarasqueta C; Unidad de Metodología, Instituto Biodonostia, Hospital Universitario Donostia, San Sebastián, España., Lobo C; Servicio de Anatomía Patológica, Hospital Universitario Donostia, San Sebastián, España., Tuneu A; Servicio de Dermatología. Hospital Universitario Donostia, San Sebastián, España.
Publikováno v:
Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2015 Jul-Aug; Vol. 106 (6), pp. 483-92. Date of Electronic Publication: 2015 Mar 19.